What’s New in ‘22 for Improving Safe Use of Anticoagulants: Special Focus on the Direct Oral Anticoagulants (DOACs)
Since the first approval in 2010, direct oral anticoagulants (DOACs) have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings. With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. Content covered in this education session will include anticoagulation stewardship and anticoagulation safety, latest literature, published best practices, reversal, peri procedural management and how Sanford Health manages a large anticoagulant service.
- Describe which anticoagulants are most commonly implicated for harms caused by medications
- Identify practices that have been shown to improve safe use of DOACs
- Discuss implementation practices to improve anticoagulation reversal and periprocedural management
Michael P. Gulseth, PharmD, BCPS, FMSHP, FASHP, program director for anticoagulation services, Sanford USD Medical Center
Michael P. Gulseth, PharmD, BCPS, FMSHP, FASHP is the program director for anticoagulation services at Sanford USD Medical Center in Sioux Falls, South Dakota. He is also a clinical associate professor, Department of Internal Medicine, at the University of South Dakota Sanford School of Medicine. Dr. Gulseth received his Doctor of Pharmacy degree in 1999 from North Dakota State University in Fargo, North Dakota. He completed residency training at United Hospital in St. Paul, Minnesota.
Dr. Gulseth is author and editor of Managing Anticoagulation Patients in the Hospital: The Inpatient Anticoagulation Service, published in 2007 by the American Society of Health-System Pharmacists (ASHP). He is a co-editor and author of Anticoagulation Therapy: A Clinical Practice Guide, 2nd edition published in 2018, by the ASHP.
Dr. Gulseth is an active member of several professional pharmacy organizations, including the ASHP, the Minnesota Society of Health-System Pharmacists (MSHP), the South Dakota Society of Health-System Pharmacists, and the American College of Clinical Pharmacy. He has served on the Editorial Advisory Board of the American Journal of Health-System Pharmacy and is a past president of MSHP. He was elected a fellow of the ASHP in 2011 and a fellow of MSHP in 2020. His research interests include evaluation of antithrombotic therapy safety and efficacy and evaluation of the benefits of anticoagulation services. He is the president and owner of Michael P Gulseth Anticoagulation Consulting, Inc.
Panelists: Michael P. Gulseth, PharmD., BCPS, FMSHP, FASHP, Sanford Health; Abby Henriks, Mayo Clinic; Ondrea Levos, PharmD, clinical pharmacy manager, ambulatory care services, M Health Fairview; Shawn Sprengeler, Sanford Health.
Facilitators: Jessica Swearingen, PharmD, BCPS, DPLA, PGY2 Health System Pharmacy Administration and Leadership Residency program coordinator, pharmacy manager and Matthew Lillyblad, PharmD, BCCCP, BCCP, PGY2 Cardiology Residency Program director; clinical pharmacy coordinator for cardiology and critical care at Allina Health
Recommended to attend
Pharmacists, emergency medicine professionals, physicians, nurses, and quality improvement teams.
The program has been designed to meet the Minnesota Board of Nursing continuing education requirements for a total of one contact hour.
- $25 per person for MHA member hospitals and health systems
- $50 per person for associate members
- $75 per person for nonmembers
Please register by noon on the day before the webinar to ensure timely delivery of access instructions.
Approximately four business days before the web conference, you will receive an email that contains instructions on how to connect. Advance registration is required to ensure delivery of instructional materials.
If you do not receive an email prior to the program with web conference details, please Contact Us to confirm your registration.